STOCK TITAN
  1. Home
  2. News
  3. OPK

Opko Health Inc - OPK STOCK NEWS

Welcome to our dedicated news page for Opko Health (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Opko Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Opko Health's position in the market.

News
Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business
Rhea-AI Summary
Labcorp (LH) to acquire select assets of BioReference Health from OPKO Health (OPK) to enhance laboratory services network and expand access to clinical laboratory services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
acquisition
-
News
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
Rhea-AI Summary
ModeX Therapeutics, an OPKO Health company, releases positive results from a Phase 1 clinical study of SAR441236, a trispecific broadly neutralizing antibody against HIV, showing promising safety and pharmacokinetic data. The study demonstrated a similar half-life to standard monoclonal antibodies, minimal anti-drug antibodies, and consistent pharmacokinetics across all dosing regimens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.51%
Tags
clinical trial
-
News
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
Rhea-AI Summary
OPKO Health, Inc. (NASDAQ: OPK) reported business highlights and financial results for the fourth quarter and full year 2023. Key highlights include advancements in ModeX's pipeline, global approvals for NGENLA, and BioReference Health's REACH program. Financially, revenue from products increased, while operating losses widened. The company also completed a significant convertible notes offering post-quarter-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.14%
Tags
earnings
News
OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024
Rhea-AI Summary
OPKO Health, Inc. (OPK) is set to announce its operating and financial results for the three and 12 months ending December 31, 2023. The company's senior management will provide a business update and discuss financial guidance during a conference call on February 27, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
conferences earnings
-
News
OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes
Rhea-AI Summary
OPKO Health, Inc. (NASDAQ: OPK) announced the closing of a private offering of $230.0 million aggregate principal amount of its Convertible Senior Notes due 2029, as well as a concurrent private placement of approximately $71.1 million aggregate principal amount of Convertible Senior Notes due 2029 to Frost Gamma Investments Trust, affiliated with the Company's Chairman and Chief Executive Officer. The Company received estimated net proceeds of approximately $221.4 million from the offering and used approximately $50.0 million of the net proceeds to repurchase shares of common stock from purchasers of Notes in privately negotiated transactions. Additionally, the Company repurchased for cash approximately $144.4 million aggregate principal amount of the Company’s outstanding 4.50% Convertible Senior Notes due 2025. The Notes and any shares of the common stock issuable upon conversion of the Notes have not been, and will not be, registered under the Securities Act of 1933, as amended.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
offering
-
News
OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
OPKO Health, Inc. (OPK) to participate in the 42nd Annual J.P. Morgan Healthcare Conference, hosting one-on-one meetings with investors and presenting on January 10th. The presentation will be webcast live and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.36%
Tags
conferences
News
OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029
Rhea-AI Summary
OPKO Health, Inc. (NASDAQ: OPK) announced the pricing of its private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029. The Notes will bear interest at a rate of 3.75% per annum, payable semiannually, and will mature on January 15, 2029. The Company also entered into separate, privately negotiated transactions to repurchase approximately $144.4 million aggregate principal amount of its outstanding 4.50% Convertible Senior Notes due 2025. The net proceeds from the offering will be approximately $192.5 million, with approximately $50.0 million to be used for repurchasing shares of common stock from purchasers of Notes in privately negotiated transactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
offering
-
News
OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029
Rhea-AI Summary
OPKO Health, Inc. (NASDAQ: OPK) announces private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029 with the option to purchase an additional $30.0 million. The Company expects to use the proceeds for repurchases of common stock and outstanding 4.50% Convertible Senior Notes due 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.33%
Tags
offering
-
News
BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing
Rhea-AI Summary
BioReference Health, LLC (BRH) has announced a strategic collaboration with Prognos Health to offer unique solutions for healthcare providers and researchers. The partnership aims to combine genetic data and critical biomarkers to provide targeted precision therapies based on patients' genetic profiles. This collaboration will utilize Prognos Health's managed real world data marketplace, which contains over 325 million de-identified patient health records, to accelerate the development and delivery of innovative therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
News
BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™
Rhea-AI Summary
SOPHiA GENETICS announced the implementation of MSK-ACCESS liquid biopsy to be commercially available for ordering by healthcare providers through BioReference and GenPath Oncology in 2024. The new offering aims to bring access to world-class liquid biopsy testing to BioReference's customers across the U.S., allowing for less invasive monitoring of cancers and expedited insights for precision medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock OPK logo
Opko Health Inc

Nasdaq:OPK

OPK Rankings

#2506 Ranked by Market Cap
#4112 Ranked by Stock Gains
N/A Ranked by Dividends

OPK Stock Data

857.30M
331.18M
52.41%
25.07%
13.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Miami

About OPK

opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-­4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-­1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig